HIGHBRIDGE CAPITAL MANAGEMENT LLC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is and the CUSIP is 10806XAD4. A total of 36 filers reported holding BRIDGEBIO PHARMA INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
HIGHBRIDGE CAPITAL MANAGEMENT LLC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$9,865,180
+102758.7%
13,000,000
-13.3%
0.41%
+16.1%
Q1 2023$9,591
+11.9%
15,000,000
-26.5%
0.35%
+49.6%
Q4 2022$8,568
-99.9%
20,400,0000.0%0.24%
+98.3%
Q3 2022$8,506,000
+3.0%
20,400,0000.0%0.12%
-36.7%
Q2 2022$8,262,000
-14.9%
20,400,0000.0%0.19%
-16.8%
Q1 2022$9,707,00020,400,0000.23%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2022
NameSharesValueWeighting ↓
INHERENT GROUP, LP 39,500,000$15,386,3964.59%
Athyrium Capital Management, LP 20,000,000$7,753,9003.26%
Diameter Capital Partners LP 43,287,000$16,786,9152.61%
Affinity Asset Advisors, LLC 10,000,000$3,895,2901.53%
DeepCurrents Investment Group LLC 39,355,000$14,590,7460.57%
BRAIDWELL LP 42,294,000$16,151,0210.54%
Context Capital Management, LLC 16,458$6,2850.46%
Aequim Alternative Investments LP 31,000,000$11,838,1250.32%
ARISTEIA CAPITAL, L.L.C. 40,816,000$15,586,6100.31%
ABSOLUTE INVESTMENT ADVISERS, LLC 5,000,000$1,875,0000.28%
View complete list of BRIDGEBIO PHARMA INC shareholders